-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Servier recently announced that the results of a phase 1 dose-escalation clinical study (NCT02481154) evaluating vorasidenib as a single agent for the treatment of isocitrate dehydrogenase (IDH) mutant advanced solid tumors (including low-grade gliomas, LGG) have been published In the famous international cancer research journal "Clinical Cancer Research"
In the first human study (NCT02481154), a total of 93 patients with advanced solid tumors with IDH1/2 mutations were enrolled, including 52 patients with gliomas
The results showed that vorasidenib showed good safety at a once-daily dose of <100 mg, and showed preliminary clinical activity in patients with relapsed or progressive IDH1/2 mutations in low-grade gliomas
Note: The original text has been deleted